Linezolid for the Treatment of Infections Caused by Methicillin Resistant Staphylococcus Aureus in Japan

Use of linezolid in patients with methicillin-resistant Staphylococcus aureus infections in Japan

Completed

Looking for future studies?

Key information

Conditions

Infections, Nosocomial Cross Infection Disease Attributes Iatrogenic Disease Infections Pathologic Processes Pathological Conditions, Signs and Symptoms

Age range

16 year and older

Sex eligibility

All sexes

Study type

Interventional

Phase

Phase 3

Primary location

Pfizer Investigational Site, Kamogawa, Chiba, Japan

Who can participate

Healthy volunteers accepted: No

Only the study team can determine whether someone qualifies for participation.

Inclusion criteria

infection due to methicillin-resistant Staphylococcus aureus

Exclusion criteria

hypersensitivity to linezolid

Treatment and study plan

Linezolid

Drug

Primary outcomes

Resolution of infection at the time of completion of therapy

Secondary outcomes

Adverse events

Sponsors and collaborators

Lead sponsor

Pfizer

Industry

Registry information

Official study title

Linezolid (PNU-10766/PNU10766SS) in the Treatment of MRSA Infections in Patients Whose Conventional Therapy Has Failed, or Who Are Intolerant to Conventional Therapy; an Open-label, Multi-center Trial

Important dates

Study start: 2003
Study completion: 2006
First posted: Sep 8, 2005
Registry last updated: May 10, 2011

OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.

View the official ClinicalTrials.gov record (opens in a new tab)

This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.

Published trials that share one or more normalized conditions with this study.

Completed